Verona Pharma PLC represents a commitment to improving the lives of patients with respiratory diseases. The company focuses on developing innovative treatments to address unmet medical needs in this field. Their corporate philosophy revolves around dedication to scientific excellence, collaboration with esteemed medical experts, and ethical conduct. Verona Pharma PLC values patient-centricity, ensuring that their research and development efforts aim to bring effective and safe therapies to those in need. Through their commitment to continuous improvement and passion for respiratory health, Verona Pharma PLC strives to make a meaningful impact on the lives of patients worldwide.

Verona Pharma PLC is primarily present in the United Kingdom and the United States.

Verona Pharma PLC has achieved several significant milestones in its journey. One notable achievement is the successful completion of Phase IIb clinical trial for its lead product candidate, RPL554, a potential treatment for chronic obstructive pulmonary disease (COPD). The company also secured positive results from a Phase IIa trial, demonstrating the safety and efficacy of RPL554 in patients with asthma. Moreover, Verona Pharma PLC received Fast Track designation from the U.S. FDA for developing RPL554 as a maintenance treatment for COPD patients. These achievements showcase the company's commitment to developing innovative and effective therapies for respiratory diseases.

Verona Pharma PLC is a pharmaceutical company focused on developing innovative treatments for respiratory diseases. Founded in 2005, the company is headquartered in London, UK. Verona Pharma specializes in the research and development of therapies targeting conditions like chronic obstructive pulmonary disease (COPD) and cystic fibrosis. With a strong clinical pipeline and a dedicated team of experts, Verona Pharma aims to address unmet needs in the respiratory field. The company's cutting-edge approach, backed by extensive research and clinical trials, positions Verona Pharma as a promising player in the healthcare industry.

The main competitors of Verona Pharma PLC in the market include pharmaceutical companies such as GlaxoSmithKline (GSK), AstraZeneca, and Novartis. These companies also focus on respiratory diseases and have a similar portfolio of products and potential treatments. Verona Pharma PLC competes with these industry leaders by offering innovative therapeutic solutions, leveraging their expertise in respiratory medicine research, and seeking regulatory approvals for their drug candidates. By analyzing market trends and addressing unmet medical needs, Verona Pharma PLC strives to differentiate itself and gain a competitive edge in the highly competitive pharmaceutical industry.

Verona Pharma PLC is primarily active in the pharmaceutical and biotechnology industries. With a focus on developing innovative therapeutic drugs, Verona Pharma PLC specializes in the research and development of treatments for respiratory diseases. By leveraging their expertise in respiratory medicine, Verona Pharma PLC aims to address unmet medical needs and improve the lives of patients suffering from conditions such as chronic obstructive pulmonary disease (COPD) and cystic fibrosis. This commitment to advancing respiratory care positions Verona Pharma PLC as a key player in the pharmaceutical industry, continually striving to provide groundbreaking solutions for respiratory health challenges.

The business model of Verona Pharma PLC revolves around the development and commercialization of innovative medications to address unmet medical needs in the field of respiratory diseases. As a biopharmaceutical company, Verona Pharma PLC focuses on discovering and developing novel drugs that target specific receptors in the airways, aimed at improving patients' health and quality of life. By leveraging their expertise in respiratory research, Verona Pharma PLC aims to bring groundbreaking treatments to the market, providing potential benefits to both patients and healthcare providers.

Коефициентът на цена спрямо печалбата (КЦП) на Verona Pharma е -108,49.

Коефициентът на цена към оборот (KUV) на Verona Pharma е 3097,92.

AlleAktien качественият резултат за Verona Pharma е 1/10.

очаквана Verona Pharma оборотът е 7,01 млн. USD.

очаквана Verona Pharma печалба е -200,26 млн. USD.

Verona Pharma PLC is a biopharmaceutical company focused on the development of prescription medications for the treatment of chronic respiratory diseases such as asthma, chronic obstructive pulmonary disease (COPD), and cystic fibrosis (CF). The company is headquartered in London, UK and is listed on the London Stock Exchange. It conducts research and development as well as clinical trials for a range of products aimed at improving the quality of life for patients with respiratory diseases. Its three main divisions are research and development, clinical studies, and commercial development. The research and development division focuses on the discovery, development, and manufacture of high-performance respiratory medications, working closely with leading scientists and researchers in the field. The clinical studies division conducts trials to evaluate the effectiveness, safety, and tolerability of new medications, collaborating with official health authorities such as the US Food and Drug Administration (FDA) to obtain necessary approvals for product marketing. The commercial development division handles marketing and sales activities for the new medications in collaboration with international partners and distribution channels. Verona Pharma currently has two products in development: Ensifentrin and RPL554. Ensifentrin is an inhaled, long-acting bronchodilator developed for the treatment of patients with COPD and CF, currently undergoing Phase III trials. RPL554, on the other hand, is an inhaled medication developed for the treatment of asthma and COPD, currently undergoing Phase II clinical trials. Both products have been recognized by the FDA as Fast Track medicines, indicating accelerated development and approval. To successfully operate its business model, Verona Pharma relies on continuous funding from shareholders, investors, and public grants. The company invests a high proportion of its resources in research and development to develop sustainable medications. This strategy has helped Verona Pharma establish a strong position as an innovative biotechnology company on the London Stock Exchange. Overall, Verona Pharma has a promising business model in the field of respiratory diseases. Through intensive research, development, and testing of innovative medications, the quality of life for patients suffering from respiratory diseases is expected to be significantly improved.

Verona Pharma разпределя дивидента от 0 USD на плащания годишно.

Дивидентата за Verona Pharma в момента не може да бъде изчислена или компанията не разпределя дивиденти.

ISIN на Verona Pharma е US9250501064.

WKN на Verona Pharma е A2N39N.

Тикерът на Verona Pharma е VRNA.

През последните 12 месеца Verona Pharma изплати дивиденда в размер на . Това съответства на дивидендна доходност от около . За следващите 12 месеца се очаква Verona Pharma да изплати дивиденда в размер на 0 USD.

Дивидентната доходност на Verona Pharma в момента е .

Verona Pharma изплаща дивидент на тримесечие. Той се разпределя в месеците .

Verona Pharma платеше дивиденда всяка година през последните 0 години.

За идните 12 месеца се очакват дивиденти в размер на 0 USD. Това съответства на дивидентна доходност от 0 %.

Verona Pharma се отнася за сектор 'Здраве'.

За да получите последното дивидентно плащане от Verona Pharma на 15.10.2024 г. в размер на 0 USD, трябваше да притежавате акцията в портфейла си преди Ex-деня на 15.10.2024 г..

Последното дивидентно плащане беше извършено на 15.10.2024 г..

През година 2023 Verona Pharma изплати 0 USD под формата на дивиденти.

Дивидентите от Verona Pharma се изплащат в USD.